HONG KONG May 24 WuXi Biologics (Cayman) Inc, a Chinese contract drug research and development company, plans to launch on Thursday an initial public offering of up to $513 million in Hong Kong, IFR reported, citing people close to the deal. The company is …
( read original story …)